Construction of new variants of dextransucrase dsr-s by genetic engineering

ABSTRACT

The present invention relates to a recombinant process for the production of truncated or mutated dextransucrases while conserving the enzymatic activity or their specificity in the synthesis of the α-1,6 bonds. The present invention relates to nucleic acid sequences of truncated or mutated dextransucrases, vectors containing the nucleic acid sequences and host cells transformed by sequences encoding truncated or mutated dextransucrases. In another aspect, the invention concerns a method for producing, in a recombinant manner, truncated or mutated dextransucrases which conserve their enzymatic activity or which conserve their specificity in the synthesis of α-1,6 bonds and can produce, from saccharose, dextrans with high molar mass and modified rheological properties compared with the properties of dextran obtained with the native enzyme and isomalto-oligosaccharides with a controlled molar mass and dextrans. The dextrans and isomalto-oligosaccharides of the invention can be used namely as texturing agents or as prebiotics.

RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.12/930,748, filed Jan. 14, 2011, which is a divisional of U.S.application Ser. No. 12/223,744, filed Nov. 11, 2008 (now U.S. Pat. No.7,897,373, issued Mar. 1, 2011), which is a U.S. National StageApplication of International Application No. PCT/IB07/00951 (filed Feb.8, 2007), claiming priority from FR 06/01117 (filed Feb. 8, 2006), saidpatent applications hereby incorporated by reference.

SUBMISSION OF SEQUENCE LISTING

The contents of the following submission of the ASCII text file of theSequence listing (file name: B6624AST25, date recorded: Jul. 25, 2012,size: 152 KB) is submitted via EFS-Web and is incorporated herein byreference in its entirety.

BACKGROUND OF THE INVENTION

The present invention relates to a recombinant process for theproduction of truncated and/or mutated dextransucrases while conservingtheir enzymatic activity and/or conserving their specificity forsynthesizing α-1,6 bonds. More precisely, the present invention relatesto nucleic acid sequences of truncated or mutated dextransucrases,vectors containing said nucleic acid sequences and host cellstransformed by sequences encoding truncated or mutated dextransucrases.In a further aspect, the invention concerns a method for producing, in arecombinant manner, truncated and/or mutated dextransucrases whichconserve their enzymatic activity and/or conserve their specificity forsynthesizing α-1,6 bonds in the final product and methods for producingdextrans or isomalto-oligosaccharides, in a single step, with acontrolled molar mass and dextrans with modified rheological properties,especially compared with the properties of dextrans obtained with thenative enzyme.

FIELD OF THE INVENTION

Dextrans are α-D-glucans with various structures, comprising contiguousglycosyl units more than 50% of which have α-1,6 bonds in the principalchain and α-1,2, α-1,3 and/or α-1,4 branches [1]. The enzymes whichproduce such dextrans from sucrose are termed dextransucrases and belongto glycoside hydrolase family 70 [2]. During the reaction, fructosederived from the sucrose is released and may be upgraded elsewhere.Dextransucrases are produced by lactic bacteria from genera Leuconostoc,Streptococcus and Lactobacillus [1].

Dextransucrase (DSR-S) from Leuconostoc mesenteroides NRRL B-512Fcontains 1,527 amino acids [3]. This enzyme catalyzes the synthesis ofglucose homopolymers with more than 95% α-1,6 bonds. The production ofdextran may be redirected towards that of oligosaccharides orglucosylated conjugates by adding a suitable acceptor to the reactionmixture [4].

The number of industrial applications for dextrans and dextranderivatives is increasing, in particular for dextrans with a specificsize. Dextrans with a size in the range 70,000 to 100,000 Da are, forexample, used as a plasma substitute [5, 31]. Further, dextran of 40,000Da is used to improve blood flow, most probably by reducing theviscosity of the blood and inhibiting erythrocytary aggregation [6,8].After sulphation, smaller dextrans of about 10,000 daltons, for example,are used as transporters for iron [7] or anticoagulants [8]. Thosecompounds may have antiviral properties [9, 10].

Further, cross-linked dextran derivatives have long been used in thefield of molecular separation; chromatography supports under the tradename Sephadex® have been sold since 1961 [6].

Moreover, the European Union has recently approved the use of dextran asa food ingredient in bakery products when these contain more than 95% ofα-1,6 bonds and have a molar mass of more than 2×10⁶ Da [15].

Dextransucrase may also produce isomalto-oligosaccharides (IMO) via anacceptor reaction. Acceptor reactions carried out by glucansucrasesconsist of a transfer of glucosyl residues from sucrose to othermolecules added to the reaction medium. It is of increasing commercialinterest, particularly in Japan, where the demand forisomalto-oligosaccharides represents about fifteen thousand tons peryear [11]. Such small IMOs (DP 2 to 6) are used in bakery items, fordrinks, in sake, in seasonings, in confectionery and as anticariogenicsweeteners. It has also been shown that said IMOs have prebioticproperties which are useful with respect to the intestinal and/orvaginal flora [12, 13]. These properties appear to vary with the size ofthe IMOs and are favored by high degrees of polymerization [14].

The only commercial and usual source of dextrans consists of cultivatingL. mesenteroides NRRL B-512F with sucrose, leading to the formation ofhigh molar mass polymers of about 10⁸ Da. The direct synthesis ofsmaller dextrans of 10000 to 100000 Da is currently impossible. Dextransare currently produced conventionally by acid hydrolysis of high molarmass native polymers followed by fractionation using organic solvents.This second step is, however, renowned for its low yields [19].

From a commercial viewpoint, IMOs of DP 2 to 6 are not produced by anacceptor reaction with dextransucrase DSR-S and glucose due to the lowreaction yields, but from starch hydrolysates and a mixture ofα-amylases and glucosidases [11].

Monchois et al [16] describe carboxy-terminal deletions from thedextransucrase of Leuconostoc mesenteroides NRRL B-512F and concludethat the role of the C-terminal domain is to facilitate transfer ofdextran and oligosaccharides beyond the active site.

U.S. Pat. No. 5,229,277 describes a process for producing dextranpolymers having a homogeneous low molar mass using Leuconostocmesenteroides and a mutant microorganism of Lipomyces starkeyi ATCC74054, which is a yeast having dextranase activity, a specific enzymefor the hydrolysis of α-1,6 bonds of dextran. That method necessitatesparticular culture conditions and a precisely regulated duration andtemperature so that the dextranase activity reduces the molar mass ofthe dextrans. Dextran polymers produced by that method have a molar massin the range of 40,000 and 150,000 Da.

The foregoing shows that there is a need for the production of dextranswith a molar mass of about 10,000 to 100,000 Da using a faster methodwith a better yield, which in particular requires neither acidhydrolysis nor fractionation.

The present invention concerns dextransucrases produced in a recombinantmanner, which are truncated and/or mutated, while conserving theirenzymatic activity and/or conserving their specificity for synthesizingα-1,6 bonds, or truncated variants of dextransucrase which producedextrans with a controlled molar mass. More precisely, they conserve thebinding specificity of native DSR-S and/or conserve their specificityfor synthesizing α-1,6 bonds and, starting from sucrose, produce highmolar mass dextrans with interesting texturing properties and/ordextrans and IMOs with a controlled molar mass.

The present invention also pertains to providing nucleic acid sequencesof truncated and/or mutated dextransucrase, vectors and host cellstransformed by said vectors, and amino acid sequences of truncatedand/or mutated dextransucrases.

In particular, as will become apparent from the Examples, certaindextransucrases produce polymers with interesting texturing properties,i.e., substantially superior to those of the polymer produced by thenative enzyme; others produce dextrans and isomalto-oligosaccharideswith a controlled molar mass. Isomaltose is produced by at least onetruncated and mutated dextransucrase.

Further aspects of the present invention will become apparent from thefollowing description and Examples or preferred implementations.

SUMMARY OF THE INVENTION

In a first aspect, the invention concerns a nucleotide sequenceconsisting essentially of or consisting of a nucleotide sequenceaccording to FIG. 1 (SEQ ID NO: 1), a nucleotide sequence according toFIG. 2 (SEQ ID NO: 2), a nucleotide sequence according to FIG. 3 (SEQ IDNO: 3), a nucleotide sequence according to FIG. 4 (SEQ ID NO: 4), anucleotide sequence according to FIG. 5 (SEQ ID NO: 5), a complementarysequence of one of the sequences with SEQ ID NO: 1, 2, 3, 4 or 5 or asequence which hybridizes with a sequence with SEQ ID NO: 1, 2, 3, 4 or5 under stringent hybridization conditions, provided that it conservesdextransucrase enzymatic activity.

In a further aspect, the invention concerns nucleotide sequences ofdextransucrase consisting essentially of or consisting of a nucleotidesequence selected from the fragment of SEQ ID NO: 1 from position 373 toposition 4269 (SEQ ID NO: 17), the fragment of sequence SEQ ID NO: 2from position 373 to position 4005 (SEQ ID NO:18), the fragment ofsequence SEQ ID NO: 3 from position 373 to position 3408 (SEQ ID NO:19),the fragment of sequence SEQ ID NO: 4 from position 373 to position 3018(SEQ ID NO:20), and the fragment of sequence SEQ ID NO: 5 from position373 to position 4269 (SEQ ID NO:21).

It also concerns nucleotide sequences consisting essentially of orconsisting of a nucleotide sequence selected from a complementarynucleotide sequence of the fragment of SEQ ID NO: 1 from the nucleotideat position 373 to that at position 4269, a complementary nucleotidesequence of the fragment of SEQ ID NO: 2 from the nucleotide at position373 to that at position 4005, a complementary nucleotide sequence of thefragment of SEQ ID NO: 3 from the nucleotide at position 373 to that atposition 3408, a complementary nucleotide sequence of the fragment ofSEQ ID NO: 4 from the nucleotide at position 373 to that at position3018 and a complementary nucleotide sequence to the fragment of SEQ IDNO: 5 from the nucleotide at position 373 to that at position 4269.

It also concerns nucleotide sequences which hybridize under stringentconditions with a nucleotide sequence selected from the fragment ofsequence SEQ ID NO: 1 from position 373 to position 4269, the fragmentof sequence SEQ ID NO: 2 from position 373 to position 4005, thefragment of sequence SEQ ID NO: 3 from position 373 to position 3408,the fragment of sequence SEQ ID NO: 4 from position 373 to position 3018and the fragment of sequence SEQ ID NO: 5 from position 373 to position4269, provided that it conserves dextransucrase enzymatic activity andsaid nucleotide sequences that hybridizes thereto has the same number ofnucleotides and hybridizes over the full length of the fragment.

In yet another aspect, the present invention concerns nucleotidesequences encoding a protein consisting essentially of or consisting ofconsecutive amino acid sequences of any one of SEQ ID NOs:6 to 10 or 22to 26.

In a still further aspect, the present invention concerns vectors, forexample plasmids, and host cells transformed by said vectors andcontaining said sequence of nucleic acids from truncated and/or mutateddextransucrase, in particular the variants of the Examples.

In a still further aspect of the present invention, the presentinvention concerns a protein encoded by said truncated and/or mutateddextransucrase nucleotide sequence selected from the fragment of SEQ IDNO: 6 from the amino acid at position 125 to the amino acid at position1423 (SEQ ID NO: 22), the fragment of SEQ ID NO: 7 from the amino acidat position 125 to the amino acid at position 1335 (SEQ ID NO: 23), thefragment of SEQ ID NO: 8 from the amino acid at position 125 to theamino acid at position 1136 (SEQ ID NO: 24), the fragment of SEQ ID NO:9 from the amino acid at position 125 to the amino acid at position 1006(SEQ ID NO: 25), and the fragment of SEQ ID NO: 10 from the amino acidat position 125 to the amino acid at position 1423 (SEQ ID NO: 26).

Further, the invention concerns a truncated and/or mutateddextransucrase consisting essentially of or consisting of one of thesequences described here, in particular selected from the fragment ofSEQ ID NO: 6 from the amino acid at position 125 to the amino acid atposition 1423 (SEQ ID NO:22), the fragment of SEQ ID NO: 7 from theamino acid at position 125 to the amino acid at position 1335 (SEQ IDNO:23), the fragment of SEQ ID NO: 8 from the amino acid at position 125to the amino acid in position 1136 (SEQ ID NO:24), the fragment of SEQID NO: 9 from the amino acid at position 125 to the amino acid atposition 1006 (SEQ ID NO:25), and the fragment of SEQ ID NO: 10 from theamino acid at position 125 to the amino acid at position 1423 (SEQ IDNO:26).

In a further aspect, the invention concerns the preparation of a mutatedand/or truncated dextransucrase by culture of host cells containing atruncated and/or mutated dextransucrase under conditions allowing theexpression of a dextransucrase, and isolating said dextransucrase fromthe culture medium.

The invention also concerns a method for producing dextrans and/orisomalto-oligosaccharides (IMO) with a controlled molar mass controlledby reacting a mutated and/or truncated dextransucrase of the inventionwith sucrose and optionally an acceptor, to obtain said dextrans or IMOwith a controlled molar mass, including isomaltose.

A method for the direct production of IMOs essentially from sucrose alsoconstitutes an aspect of the invention. The term “essentially” as usedhere means that it is not necessary for the acceptor to be employed inthe reaction.

The high molar mass dextrans of the invention have modified rheologicalproperties compared with those of dextran synthesized by a nativeenzyme, in particular a non-Newtonian, stringy and/or gelling nature.

Finally, the invention concerns compositions comprising dextransobtained by using said dextransucrases and the use of saiddextransucrases for the production of dextrans andisomalto-oligosaccharides with a controlled molar mass in the range of342 and 10⁹ Da. More precisely, the invention produces (i) isomaltose(342 Da), (ii) isomalto-oligosaccharides of 342 to 5,000 Da, (iii)dextrans with a controlled size of 1,300 to 52,000 Da, more precisely5,000 to 22,000 Da, and centered around 10,000 Da, (iv) dextrans with acontrolled size of 7,000 to 1.7×10⁵ Da, more precisely between 22,000and 70,000 Da, centered around 40,000 Da.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the amino acid (SEQ ID NO: 6) and nucleotide sequence (SEQID NO: 1) of a truncated DSR-S vardel Δ4N dextransucrase with athioredoxin tag in the 5′ terminal position of the sequence and 6histidine tags in the 3′ terminal position of the sequence as well asspacer arms between the protein tags and the sequence coding fordextransucrase.

FIG. 2 shows the amino acid (SEQ ID NO: 7) and nucleotide sequence (SEQID NO: 2) for a truncated DSR-S vardel Δ3 with a thioredoxin tag in the5′ terminal position of the sequence and 6 histidine tags in the 3′terminal position of the sequence and spacer arms between the proteintags and the sequence coding for dextransucrase.

FIG. 3 shows the amino acid (SEQ ID NO: 8) and nucleotide sequence (SEQID NO: 3) for a truncated DSR-S vardel Core with a thioredoxin tag inthe 5′ terminal position of the sequence and 6 histidine tags in the 3′terminal position of the sequence and spacer arms between the proteintags and the sequence coding for dextransucrase.

FIG. 4 shows the amino acid (SEQ ID NO: 9) and nucleotide sequence (SEQID NO: 4) for a truncated DSR-S Core ΔA with a thioredoxin tag in the 5′terminal position of the sequence and 6 histidine tags in the 3′terminal position of the sequence and spacer arms between the proteintags and the sequence coding for dextransucrase.

FIG. 5 shows the amino acid (SEQ ID NO: 10) and nucleotides sequence(SEQ ID NO: 5) for a mutant DSR-S vardel Δ4N SEV663YDA with athioredoxin tag in the 5′ terminal position of the sequence and 6histidine tags in the 3′ terminal position of the sequence and spacerarms between the protein tags and the sequence coding fordextransucrase.

FIG. 6 is a diagrammatic representation of the truncated variants ofDSR-S and their relative activity. The four different domains (i) to(iv) of DSR-S correspond to: (i) signal peptide, (ii) variable region;(iii) catalytic domain and (iv) C-terminal domain as well as the repeatunits A, C and N (in the shaded boxes) located in accordance withMonchois et al, 1998 [16].

FIG. 7 (A, B) shows anti-thioredoxin (A) and anti-6×His (B) Westernblots carried out on a DSR-S vardel Δ4N produced by E. coli TOP10 at 23°C.

FIG. 8 shows an electrophoresis gel after staining the proteins withcolloidal blue on DSR-S vardel Δ4N extracts during affinity purificationon nickel resin (Probond, Invitrogen). Track 1 corresponds to thesupernatant from sonication of E. coli TOP10 at the end of culture;track 2 corresponds to the effluent obtained after binding the tagged6×His proteins on the resin, track 3 corresponds to the elution fractionand track 4 corresponds to the elution fraction after eliminatingaggregates.

FIG. 9 shows the elution profiles obtained by HPSEC of dextrans producedby the preparation of a) native DSR-S from L. mesenteroides NRRL B-512F,b) entire recombinant DSR-S, c) DSR-S vardel Δ4N before purification andd) purified DSR-S vardel Δ4N. Peak 1 corresponds to the high molar masspolymer (HMW), peak 2 to fructose, glucose and oligosaccharides with aDP of less than 7, not separated by the system. Between those two peaks,perturbations of the base line reflect the presence of dextrans with anintermediate size (between 10³ to 10⁷ Da) in a very low concentration.

FIG. 10 A-E shows the spectra obtained by proton NMR on dextranssynthesized by A) native DSR-S from L. mesenteroides NRRL B-512F, B) theentire recombinant DSR-S, C) DSR-S vardel Δ4N before purification and D)DSR-S vardel Δ4N after purification. Spectrum E) is a carbon-13 spectrumof the dextran synthesized by purified DSR-S vardel Δ4N.

FIG. 11 corresponds to the HPAEC-PAD chromatogram of the digestionproducts using endodextranase (dase) of the four dextrans synthesized bynative DSR-S, entire recombinant DSR-S and DSR-S vardel Δ4N, before andafter purification.

FIG. 12 shows the rheological behavior of four dextrans synthesized bynative DSR-S (1) before and (2) after shearing, entire recombinant DSR-S(3) before and (4) after application of a second series of shearstresses, DSR-S vardel Δ4N (6) before and (7) after application of asecond series of shear stresses, purified DSR-S vardel Δ4N (5) where A)represents the measurement of the viscosity flow, B) dynamic modeviscosity measurements (oscillations between 0 and 10 Pa), beforedetermining the conservation G′ and energy dissipation G″ moduli for thedextrans synthesized by the non-purified DSR-S vardel Δ4N preparations(° and ; solution type behavior, G′<G″; at 5% deformation) and purifiedpreparation (□ and ▪; gel type behavior G′>G″; 0.4% deformation).

FIG. 13 shows a HPAEC-PAD chromatogram of products synthesized by mutantDSR-S vardel Δ4N SEV663YDA with 100 g/l of sucrose alone (A) or byacceptor reaction with 100 g/l of sucrose and 50 g/l of glucose (B). Thesymbol G signifies glucose, F: fructose, I₂: isomaltose, 13:isomaltotriose, N/M: nigerose or maltose (not separated by the HPAEC-padsystem) and the symbol “?” corresponds to products with an unknownstructure.

FIG. 14 shows the HPSEC chromatogram of dextrans synthesized by DSR-Svardel Δ3 at 20° C. and 10° C. The arrows correspond to the retentiontimes of commercial dextrans of 2×10⁶ Da, 70,000 and 10,000 Da whichserved as references.

FIG. 15 shows the HPSEC chromatogram of dextrans synthesized at 20° C.with 100 g/l of sucrose and with 1 U/ml of (1) DSR-S vardel Δ4N, (2)DSR-S vardel Δ3, (3) DSR-S vardel Core and (4) DSR-S Core Δ4A and theelution profile (5) of a commercial dextran of 10,000 Da (Sigma).

FIG. 16 shows the HPAEC-PAD profile of dextrans synthesized at 20° C.with 100 g/l of sucrose and with 1 U/ml of DSR-S vardel Δ4N (1), DSR-Svardel Δ3 (2), DSR-S vardel Core (3) and DSR-S vardel Core ΔA (4).

FIG. 17 shows the HPAEC-PAD profile (A) and distribution (B) of IMOsproduced by an acceptor reaction at 20° C. with the variants DSR-Svardel Δ4N (1), DSR-S vardel Δ3 (2), DSR-S vardel Core (3) and DSR-Svardel Core ΔA (4). G: glucose; F: fructose; L: leucrose; T:trehalulose; 12 to 120: isomalto-oligosaccharides with DP 2 to DP 20.The insert of Figure B corresponds to an enlargement of the IMOs from DPof 15 to 27.

DETAILED DESCRIPTION OF THE INVENTION

The term “enzyme having dextransucrase enzymatic activity” as used heremeans an enzyme which catalyzes the conversion of sucrose intooligosides and polyosides comprising more than 50% glucosyl units boundby α-1,6 bonds with a size in the range 342 and 10⁹ Da, and moreparticularly dextrans and isomalto-oligosaccharides comprising more than95% α-1,6 bonds. This conversion may take place in the presence ofabsence of external acceptors such as maltose, glucose, isomaltose orfructose or isomalto-oligosaccharides. Maltose, isomaltose and glucoseare the preferred acceptors in the present invention. The enzymaticactivity of the dextransucrases of the present invention may be measuredas described in the Examples.

The terms “nucleotides”, “polynucleotides” “nucleic acids” and“oligonucleotides” as used here are interchangeable and include, withoutbeing limited thereto, RNA, DNA, DNA/RNA sequences comprising more thanone nucleotide in a single chain or in the form of a double chain. Thepolynucleotide sequences of the present invention may be prepared by anyknown method including, without being limited thereto, any recombinantsynthesis method and any ex vivo generation method, as well ascombinations of those methods.

The term “truncated” as used here means that at least one of the N- orC-terminal ends of the amino acid or nucleic acid sequence has beenshortened. That shortening may be carried out using restriction enzymes,proteolytic enzymes or synthetically, including by specificamplification of nucleotide sequences, in particular by PCR.

The term “purified dextransucrase” as used here means a dextransucrasewhich has only one active form of dextransucrase in the preparations,which has a degree of protein purity of at least 70% or 85% or 95%.

The term “interesting original texturizing property” as used here meansthe rheological properties of the dextrans of the invention which,compared with dextrans synthesized by native enzyme under the sameconditions, for example, exhibit non-Newtonian behavior, especially agel or stringy type behavior. A “gel type polymer” is characterized hereby dynamic mode rheological measurements, detecting the energyconservation (G′) and energy dissipation (G″) moduli. For a gel, G′ ishigher than G″ over the entire frequency range studied, as will becomeapparent in Example 5. The stringy character can be identified with thenaked eye. The stringy dextrans of the invention change from solutiontype behavior to gel type behavior after application of a second seriesof shear stresses, as will also be seen in Example 5.

The following abbreviations used here have the following meanings: DSR-Sfor dextransucrase from L. mesenteroides NRRL B-512F; DP for degree ofpolymerization; HMW for “high molar mass”, IMW for “intermediate molarmass”, IMW polymers being highly polydispersed polymers with sizes inthe range 1,000 to 10⁷ Da, where separation by HPSEC is difficultbecause of their low concentration. LMW polymers (low molar mass) are,according to the invention, a population which is much higher and easilydetected between 750 and 70,000 Da, centered around 10,000 Da or in therange 2,000 to 1.7×10⁵ Da and centered around 40,000 Da.

The term “10,000 Da dextran” as used here means a population of dextranwith a size in the range 1,300 to 52,000 Da, more precisely between5,000 and 22,000 Da, and centered at the height of the peak at about10,000 Da. During characterization, the base of the elution peakobtained by gel permeation was in the range 1,300 to 52,000 Da, therange of molar mass estimated at the elution peak half height was in therange from 5,000 to 22,000 Da and the peak was centered at the height ofthe peak at about a mass of 10,000 Da. When the molar mass was expressedat the peak half height, at least 50% of the dextran population fellwithin the indicated range.

The term “40,000 Da dextran” as used here means a population of dextranwith a size in the range 7000 to 1.7×10⁵ Da, more precisely between22,000 and 70,000 Da, and centered at the height of the peak at about40,000 Da. During characterization, the base of the elution peakobtained by gel permeation was in the range 7,000 to 1.7×10⁵ Da, therange of molar mass estimated at the elution peak half height was in therange 22,000 to 70,000 Da and the peak was centered at a mass of about40,000 Da. When the molar mass was expressed at the peak half height, atleast 50% of the dextran population fell within the indicated range.

IMO Means Isomalto-Oligosaccharides.

The term “consisting essentially of” when used in connection withnucleic acids or amino acids as used here means that other minoringredients or molecules may be present with the amino acid or nucleicacid sequences. The nucleic acid sequence has the exact same length asindicated in the sequence identification number, but may have 3 to 12extra nucleotides at the N- and C-terminals. Like wise, the amino acidsequence has the exact same length as indicated in the sequenceidentification number but from 1 to 4 extra amino acids may be added atthe N- or C-terminals. These extra amino acids have no effect on theenzyme activity.

More specifically, the present invention concerns nucleic acids whichencode a truncated dextransucrase or a mutated dextransucrase, asequence complementary to all or part of those sequences or a sequencewhich hybridizes under stringent conditions with one of the abovesequences provided that dextransucrase enzymatic activity is maintained.It should be appreciated that the nucleotide sequences that hybridizesthereto has the same number of nucleotides and hybridizes over the fulllength of the fragment.

The term “stringent hybridization conditions” as used here meansconditions as described by Sambrook et al, Molecular Cloning Manual,3^(rd) edition (2001), i.e., as an example, the following conditions:hybridization buffers: 2×SSC, 10×Denhardts solution (Ficoll 400 & PEG &BSA, ratio 1:1:1), 0.1% SDS, 5 mM EDTA, 50 mM Na₂HPO₄, 250 μg/ml herringsperm DNA, 50 μg/ml of t-RNA or 0.25 M of sodium phosphate buffer with apH of 7.2, 1 mM EDTA, 7% SDS;

Hybridization temperature: 60° C.;

Washing buffer: 2×SSC, 0.1% SDS;

Washing temperature: 60° C.

The nucleic acid molecules which hybridize under stringent conditionswith the nucleic acids of the present invention may in principle encodedextransucrases from any microorganism such as bacteria, gram positivebacteria and, in one aspect of the invention, bacteria from the generaLeuconostoc, Streptococcus or Lactobacillus.

The present invention concerns nucleic acids which encode dextransucraseproteins having at least 70% or 80% or 90% sequence identity with thoseof sequences SEQ ID NOs: 1 to SEQ ID NO: 5 and SEQ ID NOs 17 to 21,provided that the protein encoded by said sequences has dextransucraseenzymatic activity.

In another aspect, the present invention concerns nucleotide sequencesencoding a protein consisting essentially of or consisting ofconsecutive amino acid sequences of any one of SEQ ID NOs:6 to 10 or 22to 26.

In a further aspect of the invention, the sequences complementary to thesequences of the invention or sequences which hybridize with saidsequences under stringent conditions, provided that dextransucraseenzymatic activity is maintained, are also included in the presentinvention.

Derivations from the basic nucleotide sequences SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5), where the sequences areselected from the fragment of sequence SEQ ID NO: 1 from position 373 toposition 4269, the fragment of sequence SEQ ID NO: 2 from position 373to position 4005, the fragment of sequence SEQ ID NO: 3 from position373 to position 3408, the fragment of sequence SEQ ID NO: 4 fromposition 373 to position 3018 and the fragment of sequence SEQ ID NO: 5of a nucleotide in position 373 to position 4269, the sequencescomplementary to said sequences or sequences which hybridize with saidsequences under stringent conditions provided that the dextransucraseenzymatic activity is maintained, may be produced by deletion,substitution, insertion or recombination, for example; the methods forcarrying out said steps and transformations being well known in the artand described, for example, by Sambrook et al, supra.

It should be understood here that if any deletions, substitutions,insertions or recombinations of any of the sequences cited above takeplace, the proteins encoded by the sequences must maintain theirdextransucrase enzymatic activity. Thus, 1 to 132, preferably 2 to 60nucleotides, more preferably 15 to 36 nucleotides and still morepreferably 12 to 27 nucleotides may be modified, for example, bydeletion, substitution, insertion or recombination. According to theinvention, 90%, preferably 95% of the nucleotides remain unchanged.

The dextransucrase enzymatic activity can be measured, as described inthe method section and in the Examples of the present application.

The oligonucleotides which may be used as a probe or primer are, forexample, SEQ ID NO: 1 to SEQ ID NO: 5 or nucleotide sequences selectedfrom the fragment of sequence SEQ ID NO: 1 from position 373 to position4269, the fragment of sequence SEQ ID NO: 2 from position 373 toposition 4005, the fragment of sequence SEQ ID NO: 3 from position 373to position 3408, the fragment of sequence SEQ ID NO: 4 from position373 to position 3018 and the fragment of sequence SEQ ID NO: 5 from anucleotide in position 373 to position 4269.

The length of the probes and primers can vary depending on theirapplications. In general, they must have at least 25 nucleotides and maycomprise all of the dextransucrase sequences described, such as 3,896nucleotides. The length can also vary to be in the range of 25 to 150nucleotides, 25 and 800 nucleotides or 25 and 3000 nucleotides, forexample.

The primers generally comprise 18 to 25 nucleotides in length, but mayalso be longer, depending on the envisaged application. Examples ofprimers which can be used in the present invention are:

(SEQ ID NO: 11) GGC TTC TCT GGT GTG ATT (SEQ ID NO: 12)GAT CTG TCA GAA ACT GGC (SEQ ID NO: 13) ACA CAA CAA GTT AGC GGC(SEQ ID NO: 14) CCA GAT ACT AAC TTG AGT (SEQ ID NO: 15)TTC ATT GAT GCA GAC GGG (SEQ ID NO: 16) CAC GAC TAC GAC GCG CAA

It should be noted that the primers in the 5′ and 3′ terminal positionsof the nucleotides encode the dextransucrase (SEQ ID NOs: 11 to 15) andthe 5′ and 3′ side of the mutant sequence (SEQ ID NO: 16). However, askilled person can use each of these sequences to produce primers orprobes using consecutive nucleotides. Furthermore, these nucleotidesequences which are used as a probe may be tagged with radioactivity,enzymatic tagging, fluorescent tagging, in particular.

In order to genetically engineer the prokaryotic or eukaryotic cell, thenucleic acids of the present application or a portion of the nucleicacids of the present application may be introduced into plasmids thatallow mutagenesis or modification of sequences by recombination ofnucleotide sequences. Standard methods using these techniques are knownto the skilled person and have been described by Sambrook et al, supra,in particular. The DNA fragments can also be connected to each other byadapters or links and suitable restriction enzymes can be used to removecertain DNA sequences. Methods such as mutagenesis, restriction afterthe restoration of primers or ligatures can be used to obtain thedesired sequence with the appropriate insertions, deletions or necessaryor desirable substitutions.

Furthermore, well defined tags coding for nucleic acids may be attachedto the N- or C-terminal ends of the nucleic acid sequences of thepresent invention. They may be peptides such as poly-His, c-myc epitopeor HA-tag or small proteins such as bacterial GST, MBP (maltose bindingprotein), thioredoxin, 3-galactosidase, VSV-glycoprotein and the like.

Particular nucleic acids coding for other protein tags are His-tag,T7tag, S-tag, a “flag” peptide, trpE, avidin/streptavidin,staphylococcal A or G protein, dihydrofolate reductase, cellulosebinding domains, polycysteine, polyphenylalanine and the like, which mayalso be used in the present invention.

According to one aspect of the present invention, a nucleic acid codingfor a thioredoxin is fused to the N-terminal nucleic acid sequence. Anucleic acid coding for a 6×His tag is fused to the 3′ end of thenucleic acid sequences.

The nucleic acids of the present invention may be linked to atranscription unit comprising (1) gene expression regulation elementssuch as promoters and amplifiers and (2) a coding or structural sequencewhich is transcribed into a mRNA and translated into the correspondingprotein, and (3) appropriate initiation and termination signals.

A number of suitable expression control sequences are known in the art.General methods for expressing the recombinant protein are also knownand exemplified in the document by R Kaufman, Methods in Enzymology 185,537-566 (1990) [17].

The promoter regions which can be used in the vectors of the presentinvention include lacL, lacZ, T3, T7, gpt, lambda PR, tre and ara.

The present invention also concerns vectors, in particular plasmids,cosmids, viruses, bacteriophages and other vectors which are known inthe genetic engineering field and which comprise the nucleic acidsequences of the present application in one aspect of the presentinvention, said vectors being plasmids and selected from DSR-S vardelΔ4N, DSR-S vardel Δ3, DSR-S vardel Core, DSR-S Core ΔA and DSR-S vardelΔ4N SEV663YDA.

The nucleic acids of the present invention may be expressed inprokaryotic or eukaryotic cells. Non-limiting examples of such cellswhich may be cited are VERO cells, HELA cells such as ATCC No CCL3, CHOcell lines such as ATCC CCL61, COS cells such as COS-7 and ATCC No CRcells: 1650, W138, BHK, HepG2, 3T3 such as ATCC No CRL6361, Δ549, PC12,K562, 293 cells, Sf9 cells such as ATCC No CRL 1711, Cv1 cells such asATCC No CCL70 and JRKAT cells such as ATCC Tib152.

Non-limiting cells which can be used in the present application includestrains of the prokaryotic host cells such as Eschierichia coli,Bacillus subtilis, Salmonella typhimurium or strains of the genusPseudomonas, Streptomyces and Staphylococcus or strains of eukaryotichost cells such as the parasites Apicomplexan (Plasmodia, Toxoplasma,Cryptosporidia), Leishmania or Trypanosoma.

Other appropriate cells may be used in the present invention and inparticular include yeast cells such as Saccharomyces, for exampleSaccharomyces cerevisiae or pombe, Pichia pastoris and eukaryotic cells(plant cells, CHO cells and the like).

In a further aspect, the cells used for expressing nucleic acids of thepresent invention are Escherichia coli and strains selected, forexample, from JM109, BL21(DE3)pLysS, TOP10 or Pir1. The INVsc strain ofSaccharomyces cerevisiae may also be used.

The present invention concerns host cells transformed with the nucleicacid sequences described above or with a vector as described above andcells derived from transformed cells and containing the vector or thenucleic acid sequences described herein.

Examples of such host cells which may be cited are Escherichia coli, inwhich the truncated and/or mutated dextransucrase may be produced. Thepreparation of such host cells is known in the art.

Proteins and biologically active fragments of such proteins as well asmutated proteins which are encoded by the nucleic acid molecules of thepresent invention and their preparation methods also fall within thescope of the present invention.

Thus, the present invention concerns a method for preparing mutatedand/or truncated dextransucrase, comprising the following steps:

-   -   (a) culturing host cells transformed with the nucleic acid        sequences described above or with a vector as described above        under conditions allowing the expression of a dextransucrase;        and    -   (b) isolating said dextransucrase from the culture medium.

More specifically, the nucleic acid sequences may be selected from SEQID NO: 1 from position 373 to position 4269, the fragment of sequenceSEQ ID NO: 2 from position 373 to position 4005, the fragment ofsequence SEQ ID NO: 3 from position 373 to position 3408, the fragmentof sequence SEQ ID NO: 4 from precursor 373 to position 3018, and thefragment of sequence SEQ ID NO: 5 from position 373 to position 4269,complementary sequences of said sequences and sequences which hybridizewith said sequences under stringent conditions, provided thatdextransucrase enzymatic activity is maintained.

After being isolated, the dextransucrases of the present invention mayalso be purified. In this respect, the usual purification methods may beused such as precipitation, ion exchange chromatography, affinitychromatography, hydrophobic exchange chromatography, gel filtration,reverse phase HPLC, phase demixing and the like. In one aspect of thepresent invention, the mutated or truncated dextransucrases of thepresent invention may be purified using a resin charged with nickel,taking into account the existence of the thioredoxin and 6×His tag.

Another aspect of the present invention concerns dextransucrase proteinsconsisting essentially of or consisting of an amino acid sequenceselected from SEQ ID NO: 6 to 10 or an amino acid sequence selected fromthe fragment of SEQ ID NO: 6 from the amino acid at position 125 to theamino acid at position 1423, the fragment of SEQ ID NO: 7 from the aminoacid at position 125 to the amino acid at position 1335, the fragment ofSEQ ID NO: 8 from the amino acid at position 125 to the amino acid atposition 1136, the fragment of SEQ ID NO: 9 from the amino acid atposition 125 to the amino acid at position 1006, and the fragment of SEQID NO: 10 from the amino acid at position 125 to the amino acid atposition 1423.

A protein encoded by one of nucleotide sequences SEQ ID NO: 1 to SEQ IDNO: 5 or fragments of said sequences, as set forth above, is anotherembodiment of the present invention.

Homologous amino acid sequences, i.e., wherein the degree of similaritywith the sequences defined above is sufficient for the enzymaticactivity to be maintained, are also included in the subject matter ofthe present application. Thus, Blast and Fasta programs may be used toinvestigate similarity. Since it was demonstrated herein that it waspossible to truncate the N- and C-terminal ends of dextransucrases,maintaining enzymatic activity, sequence similarity cannot be consideredfor just the single complete sequence, but also for the truncatedsequences. The present invention thus concerns any sequence containing80%, 90% or 98% sequence similarity with the complete sequence, but alsothose which would have 80%, 90% or 98% sequence similarity with one ofthe truncated sequences, provided that enzymatic activity is maintained.

More specifically, the present invention concerns sequences having adegree of similarity of the order of 90%, 95% or 98% similarity with SEQID NO: 6 to 10 or amino acid sequences selected from the fragment of SEQID NO: 6 from the amino acid at position 125 to the amino acid atposition 1423, SEQ ID NO: 7 from the amino acid at position 125 to theamino acid at position 1335, SEQ ID NO: 8 from the amino acid atposition 125 to the amino acid at position 1136, SEQ ID NO: 9 from theamino acid at position 125 to the amino acid at position 1006, and SEQID NO: 10 from the amino acid at position 125 to the amino acid atposition 1423, provided that these proteins have the enzymatic activityof said dextransucrases. Clearly, the amino acid sequences with aspecific identity defined above have a majority of conservative aminoacid substitutions.

Conservative amino acid substitutions include amino acid substitutionsof the same class. These classes comprise, for example, amino acidshaving uncharged polar side chains, such as Asn, Gln, Ser, Thr or Tyr;amino acids containing basic side chains, such as H is, Lys or Arg;amino acids containing acidic side chains, such as Glu or Asp and aminoacids containing non-polar side chains, such as Ala, Gly, Leu, Val, Ile,Phe, Cys or Trp.

Furthermore, concerning the enzymatic activity of dextransucrase withamino acid substitutions, this can be tested as set forth in theExamples, but the activity can also be evaluated by HPLC analyses orusing the usual predictions concerning the way amino acid changes affectprotein functions.

In a further aspect, since the amino acid sequences are indicated here,the protein may be synthesized using R B Merrifield's method, 1963 [20].For this reason, the synthesized dextransucrase proteins constituteanother aspect of the present invention.

The present invention also concerns mutant dextransucrases designatedmutant SEV663YDA of DSR-S vardel Δ4N in which the serine, glutamic acidand valine in positions 663, 664 and 665 have been modified to tyrosine,aspartic acid and alanine respectively.

This mutant may be used to synthesize isomaltose from sucrose, usingsucrose as the only substrate in a yield which is equivalent to thatobtained when an acceptor, such as glucose is added to the reactionmedium.

For this reason, the present invention concerns a method for producingisomaltose directly from sucrose, said method comprising reacting mutantdextransucrase with SEQ ID NO: 10 with sucrose, and producingisomaltose.

The fusion proteins containing a protein tag as described above alsoform part of the present invention. In this regard, the mutated and/ortruncated proteins of the present invention may be fused with at leastone protein tag.

The preparation of high molar mass dextrans (about 10⁶-10⁸ Da) and withmodified rheological properties compared with dextran synthesized bynative DSR-S of L. mesenteroides NRRL B-512F using the truncateddextransucrase of the present invention is another aspect of theinvention.

More specifically, microorganisms secreting dextransucrase or cellularextracts of microorganisms producing dextransucrase in an intracellularmanner may be cultivated or used in a medium comprising sucrose,resulting in the synthesis of isomaltose (342 Da), (ii)isomalto-oligosaccharides of 342 to 5,000 Da, (iii) dextrans with acontrolled size of 1,300 to 5,200 Da centered around 10,000 Da, (iv)dextrans with a controlled size of 7,000 to 1.7×10⁵ Da centered around40,000 Da, and (v) dextrans with a high molar mass from 2×10⁶ Da to 10⁹Da. These compounds may be isolated from the culture medium byconventional methods such as ultrafiltration, nanofiltration, alcoholicprecipitation, liquid chromatography and the like.

Alternatively, the truncated and/or mutated dextransucrases described inthe present invention may be purified and used in a method for producingdextrans with a controlled molar mass.

Thus, the invention concerns a method for producing dextrans and/orisomalto-oligosaccharides with a controlled molar mass, comprisingreacting a mutated and/or truncated dextransucrase consistingessentially of or consisting of a sequence selected from nucleotidesequences SEQ ID NO: 6 to SEQ ID NO: 10 defined above with at leastsucrose and optionally an acceptor.

The invention also concerns a method for producing isomaltose, themethod comprising reacting a mutated and/or truncated dextransucrasewith sequence SEQ ID NO: 10 essentially with sucrose. The invention alsoconcerns a method for producing dextrans with interesting texturalproperties, the method comprising reacting a mutated and/or truncateddextransucrase with the sequence of SEQ ID NO: 6.

The invention also concerns dextrans and isomalto-oligosaccharideshaving the characteristics defined in the present application which maybe obtained by the methods described here. These characteristicproperties include the fact that high molar mass dextrans havenon-Newtonian behavior and have the character of a gel or a stringynature, and the property of changing form a solution type behavior tothat of a gel after application of a second series of shear stresses.

As will become apparent in the Examples, advantageously, the differentrheological properties may be obtained depending on whether the enzymeis purified or non-purified.

The enzymatically produced dextrans of the invention may be used as asupport in the pharmaceutical industry, as a plasma substitute,additives in textiles or paints, in cosmetics and in the agroalimentaryindustry, as well as a texturing agent, for example as a substitute forgum Arabic or a gelling agent. The invention also concerns compositionscomprising the dextrans and IMOs of the invention.

One important application of the dextrans and isomalto-oligosaccharidesof the present application is their use as prebiotics. These productsare not completely metabolized and are selectively fermented in thecolon by appropriate bacterial species such as Bifidobacteria andLactobacilli.

Oligosaccharides have traditionally been used for human or animalfoodstuffs, in the pharmaceutical industries and in the cosmeticsindustry or as a sweetener, stabilizer or filler [21]. During the lastfifteen years, a new field of activity has developed for the prebioticproperties of certain non digestible molecules [23]. Oligosaccharides asprebiotics are interesting with respect to their capacity to resistattack by digestive enzymes and to accentuate the growth of “healthy”bacteria, primarily Bifidobacteria and Lactobacilli, in the intestine.This concept has been stimulated by the emergence of commercialprebiotic products which have rapidly gained popularity. Oligomers suchas fructo-oligosaccharides, lactulose, galacto-oligosaccharides,xylo-oligosaccharides, oligosaccharides extracted from soya orisomalto-oligosaccharides which are usually obtained by biologicalprocesses or by extraction from plants, are also promising. Currently,research in this field has centered on the production of noveloligosaccharide structures termed second generation prebiotics whichshould have novel physico-chemical properties and more specificbiological activities [18].

In a further aspect, the present invention concerns a compositioncomprising a dextran obtained from a dextransucrase of the invention,and a pharmaceutically acceptable vehicle or a food quality vehicle.

The acceptable vehicle may, for example, be selected from adjuvants,salts and the like and the adjuvants may be selected from muramylpeptides, alum, montanide and the like. The mutated and/or truncateddextransucrases may be a purified protein, a protein produced in arecombinant manner or a synthetically produced protein.

Regarding the method for producing the dextrans and/or IMOs, preferredacceptors, when used, are glucose, isomaltose, maltose andisomalto-oligosaccharides.

Preferably, the method for producing isomalto-oligosaccharides with acontrolled molar mass comprises reacting a mutated and/or truncateddextransucrase consisting of sequences SEQ ID NO: 7, 8, 9 or 10essentially with sucrose. The degree of polymerization thus varies from2 to 60 glucosyl units (DP2 to DP60).

The production reaction takes place at temperatures in the range 4° C.to 80° C., preferably 4° C. to 40° C.

Preferably, when the sequence is SEQ ID NO: 7, SEQ ID NO: 8 or SEQ IDNO: 9, the temperature is in the range 4° C. to 15° C., preferably 8° C.to 12° C., and more preferably the temperature is of the order of 10° C.for the production of dextrans with a controlled size. Further, for suchsequences, the temperature is preferably in the range from about 8° C.to 25° C., more preferably on the order of 20° C. for IMO synthesis.

Furthermore, preferably when the sequence is SEQ ID NO: 6 or SEQ ID NO:10, the temperature is in the range 15° C. to 45° C., preferably 17° C.to 30° C., and more preferably on the order of 20° C. to 25° C.

Further, the sucrose concentration is in the range 10 to 600 g/l,preferably 75 to 400 g/l, and more preferably 90 to 280 g/l.

When the sequence is SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, theconcentration of sucrose in the medium is preferably on the order of 250g/l.

Further, when the sequence is SEQ ID NO: 6 or SEQ ID NO: 10, theconcentration of sucrose may be on the order of 100 g/l.

Further, as appropriate, the sucrose/acceptor weight ratio may be on theorder of 0.5 to 12, preferably 1 to 4, more preferably about 2.

In the method of the invention, the dextransucrase is in the free formor immobilized on a support. Said immobilization may be effected byadsorption, inclusion or covalent binding, for example.

Finally, to carry out the method, the pH is in the range 3.0 to 10.0,preferably 4.0 to 7.0, more preferably 4.5 to 6.0 and still morepreferably about 5.2.

Other aspects of the invention may become apparent from a study of theExamples below.

Example 1 Construction of Variants

The pBad/TOPO Thiofusion vector (Invitrogen) was used for cloning andexpressing truncated and/or mutated dsrS genes under the control of theL-arabinose promoter. It allows fusion of the gene to the 6×His tag atthe C-terminal end, and to a thioredoxin tag at the N-terminal end.

For use as a matrix, genomic DNA from L. mesenteroides NRRL B-512F wasextracted using the “Blood and Cell culture DNA maxi” kit (Qiagen). Thestrain is derived from the NCAUR collection, Peoria, Ill., USA.

One Shot TOP10 cells (Invitrogen) were used for expression of thetruncated and/or mutated dsrS genes. The restriction enzymes werepurchased from New England Biolabs and used in accordance with themanufacturer's instructions. DNA was purified using “QIAquick”(purification by PCR and gel extraction) and “QIAprep” (plasmidpurification) kits from Qiagen.

The variants were constructed by PCR amplification of the DSR-S genefrom genomic DNA from L. mesenteroides NRRL B-512F using the “ExpandHigh fidelity” polymerase (Roche) and the following primers (given inthe 5′→3′ direction):

-   -   1 DSR-S vardel Δ4N was constructed using the pBad and DSR-S        vardel primers: 454-acacaacaagttagcggcaagtacgttgaaaaagac-490 and        PBad Δ4N: 4350-acteaagttagtatctggatccacaatgatagc-4317. It        contained amino acids T152 to S1450 of DSR-S.    -   2 DSR-S vardel Δ3 was constructed using the PBad and DSR-S        vardel primers: 454-acacaacaagttagcggcaagtacgttgaaaaagac-490 and        PBad Δ3: 4086-cccgtctgcatcaatgaattcacc-4062. It contained amino        acids T152 to G1362 of DSR-S.    -   3 DSR-S vardel Core was constructed using the PBad and DSR-S        vardel primers: 454-acacaacaagttagcggcaagtacgttgaaaaagac-490 and        PBad Core: 3489-gccagtttctgacagatcattagttaactg-3459. It        contained amino acids T152 to G1162 of DSR-S.    -   4 DSR-S Core ΔA was constructed using the PBad DSR-S cat        primers: 843-ggcttetctggtgtgattgatggtcaa-870 and PBad Core:        3489-gccagtttctgacagatcattagttaactg-3459. It contains amino        acids G282 to G1162 of DSR-S.    -   5 The mutant DSR-S vardel Δ4N SEV663YDA was constructed by        directed mutagenesis using the “mega primer” technique [33, 21]        and DNA polymerase Pfu (Strategene). A first PCR reaction was        carried out using the DSR-S vardel Δ4N plasmid matrix and the        SEV663YDA primer pair:        1965-agattgtacgagctcacgactacgacgcgcaaacggtt-2004 and rev:        3447-gtcaccatcctcagtsgttcgaaacg-3422, comprising the BstBI        restriction site (underlined). This PCR product was then used as        a reverse mega primer in a second PCR with the forw primer:        1329-caaccacagtggaatgaaactagtc-1354 comprising the SpeI        restriction site. This second PCR product was then digested with        the two restriction enzymes SpeI and BstBI in accordance with        the manufacturer's conditions (New England Biolabs) and cloned        into the pBad DSR-S vardel Δ4N vector previously digested with        the same enzymes. The SEV663YDA primer was designed to introduce        a single restriction site to select positive clones (in this        case, the Sad site).

The primary structure of each of the variants DSR-S vardel Δ4N, DSR-Svardel Δ3, DSR-S vardel Core and DSR-S Core ΔA is diagrammatically shownin FIG. 6.

Example 2 Production of Variants in E. coli

Cultures were carried out in a baffled Erlenmeyer flask on 2×YT mediumbuffered to a pH of 6.4 with 100 mN of Tris-HCl, DSR-S being known to beunstable under alkaline pH conditions [3].

Composition of Medium 2×YT:

Bactotryptone 16 g/l Yeast extract 10 g/l NaCl 5 g/l Tris 12.1 g/l

E. coli TOP10 cells carrying pBad DSR-S vardel Δ4N and pBad DSR-S vardelΔ4N SEV663YDA plasmids were cultivated at 23° C. L arabinose inductionwas carried out when cell growth reached OD_(600nm) of 0.2 with 0.002%(w/v) of inducer. Culturing was stopped when cell growth reached aplateau (OD_(600nm) of about 3-3.5) before starting the cell lysisphase.

E. coli TOP10 cells carrying pBad DSR-S vardel Δ3, pBad DSR-S vardelCore and pBad DSR-S Core ΔA plasmids were brought to 16° C. Inductionwas carried out when the cell growth reached OD_(600nm) of 0.2 with0.005% (w/v) of L arabinose in the case of DSR-S vardel Δ3 and 0.02%(w/v) in the case of DSR-S vardel Core and DSR-S Core AA. Culturing washalted when the cell growth reached a plateau (OD_(600nm) of about 2.5)before starting the cell lysis phase.

Following culture, the cells were recovered by centrifuging (8,000×g, 10minutes, 4° C.), re-suspended and concentrated to an OD_(600nm) ofequivalent to 80 in a sodium acetate buffer 50 mM, pH 5.2, supplementedwith 0.05 of 1 mM CaCl₂ and phenylmethanesulfonyl fluoride (PMSF). Cellrupture was carried out by sonication. The preparations were thencentrifuged once again (20,000×g, 30 min, 4° C.) to eliminate cellulardebris and recover only the sonication supernatant.

The enzymatic activity of the extracts was measured using thedinitrosalicylic acid (DNS) method of Sumner and Howell, 1935 [22]. Anenzymatic unit is defined as the quantity of enzyme which catalyses theformation of one μmole of fructose per minute at a given temperature (4°C. to 40° C. depending on the case, more precisely 20° C. or 30° C.) andin a sodium acetate buffer (50 mM), pH 5.2, containing 0.05 g/l of CaCl₂and 100 g/l of sucrose.

Example 3 Purification of DSR-S Vardel Δ4N Variant

Different enzymatic forms of DSR-S vardel Δ4N were produced during theculture of E. coli TOP10: a vastly major entire form and differentdegraded forms at the C-terminal end (FIG. 7). The origin of thesedegradations remains unclear. Production in Example 2 reached about 5500U/l of culture in the sonication supernatants (activity assayed at 30°C.).

To determine the number of active enzymatic forms in the extracts,electrophoresis gels were produced under native or denaturingconditions. After gel re-naturing, it was incubated overnight at 25° C.in a sodium acetate buffer, 50 mM, pH 5.2 supplemented with 100 g/l ofsucrose. The active enzymatic forms then synthesized polymer at theregion to which they migrated in the gel. A reagent (Schiff's reagent)which specifically colored the polymers synthesized by activedextransucrases, after oxidation of primary alcohol functions of theperiodic acid polymer was used and the gels were stained with thisreagent. This type of gel is termed a zymogram. In the case of DSR-Svardel Δ4N, or its mutant SEV663YDA, only the two higher molar massforms were detected as being active (results not shown). However, onlythe entire form had both the thioredoxin tag and the 6×His tag.

The presence of the 6×His tag only in the entire form of DSR-S vardelΔ4N was exploited to purify the enzyme by affinity chromatography onnickel resin (Probond Ni-NTA, Invitrogen).

Purification was carried out at 4° C. All of the buffers hadconcentrations of 50 mM sodium acetate, 400 mM of NaCl, differentconcentrations of imidazole and were adjusted to a pH of 7.5. The resinwas equilibrated with 8 volumes of buffer having a concentration of 40mM of imidazole. Fixing was carried out for 2 hours with 7 volumes ofenzymatic extract supplemented with 20 mM of imidazole and adjusted to apH of 7.5. Next, the resin was washed with 40 volumes of 40 mM imidazolebuffer, 8 volumes at 60 mM and 4 volumes at 100 mM. Finally, theproteins were eluted with 7 volumes of buffer having a concentration of250 mM of imidazole.

The fractions containing the eluted fusion proteins were mixed anddialyzed overnight at 4° C. against a buffer containing a concentrationof 50 mM of sodium acetate, pH of 5.2, and 0.05 g/l of CaCl₂. Theprotein concentration was determined by the microbradford method (BioradLaboratories) with BSA (bovine serum albumin) as the standard.

The purity of the preparation at the end of the procedure was estimatedat about 90% (FIG. 8). The purified DSR-S vardel Δ4N proteins had a verystrong tendency to aggregate, causing the formation of whiteprecipitates and limiting the yields obtained at the end of theprocedure (Table 1). However, the specific activity of the preparationwas estimated at 584 U/mg of protein, which corresponded to the bestdescribed specific activity of a recombinant dextransucrase. By way ofcomparison, the specific activity of native DSR-S (expressed by L.mesenteroides NRRL B-512F) was estimated at about 170 U/mg [24].

TABLE 1 Purification of DSR-S vardel Δ4N by affinity chromatography onnickel resin Protein Specific Purification Volume Activity conc activityPurification Yield stage (ml) (U/ml) (mg/l) (U/mg) factor (%) Sonication150 149.2 9.46 15.7 1 100 supernatants Elution 150 67.6 0.25 270.5 1745.3 fraction after dialysis Soluble 150 38.2 0.09 424.4 27 25.4fraction after eliminating aggregates

Example 4 Nucleotide Sequences and Amino Acid Sequences

The constructs were sequenced and the corresponding sequences are shownin FIGS. 1 to 5.

Example 5 Synthesis of Dextran by DSR-S Vardel Δ4N, Comparison withDSR-S from L. mesenteroides NRRL B-512F

Dextran was synthesized from native DSR-S from L. mesenteroides NRRLB-512F, entire recombinant DSR-S (sonication supernatant) and DSR-Svardel Δ4N (sonication supernatant and purified enzyme).

Synthesis Conditions and Analysis of Products Formed

Entire recombinant DSR-S was constructed on the same principle as thevariants described in Example 1, with primers which were suitable foramplification of the entire gene. E. coli TOP10 cells carrying the pBadDSR-S plasmid were cultivated using the protocol described for DSR-Svardel Δ4N (Example 2). The supernatant contained three enzymatic forms,including two with higher active molar mass.

The form with the greatest size contained DSR-S in its entirety; the twoother forms were degraded at their N-terminal position (data not shown).

The activity of each enzymatic preparation was determined at 30° C.

Dextran syntheses were carried out at 25° C. starting with a 100 g/lsucrose solution, in a 50 mM sodium acetate buffer containing 0.05 g/lof CaCl₂ and with 1 unit per ml of enzyme. The progressive exhaustion ofsucrose was monitored by HPAEC-PAD analyses (see below) and the reactionwas stopped after its complete consumption, by heating for 5 min at 95°C. (complete denaturing of cited dextransucrases).

The products formed were analyzed by HPAEC-PAD (high performance anionexchange chromatography with pulsed amperometric detection) with respectto the mono, di and oligosaccharides, and by HPSEC (high performancesize exclusion chromatography) with respect to the polysaccharides.

The HPAEC-PAD system comprised a Dionex “Carbopack PA100” 4×250 mmcolumn. A 6 to 300 mM sodium acetate gradient in 28 minutes in a 150 mMsodium hydroxide solution was applied at a flow rate of 1 ml/min.Detection was carried out by amperometry using a Dionex ED40 module witha gold electrode and an Ag/AgCl pH reference electrode.

The HPSEC system was constituted by two Shodex OH-Pack SB-805 andSB-802.5 columns in series, using 0.45 M sodium nitrate+1% (v/v)ethylene glycol as the solvent, in an amount of 0.3 ml/min. The columnsand pre-columns were kept at 70° C. and the samples were filtered on0.45 μm filters (Sartorius) prior to injection. Detection was of therefractometric type, coupled to a light diffusion detector (Wyatt) todetermine the mass of the dextrans.

The concentrations by weight of glucose, fructose and leucrose (sucroseisomer) were determined by HPAEC-PAD analyses. The percentages ofglucosyl residues from the sucrose incorporated into the free glucoseand leucrose were calculated using the following formula:

% G _(glucose)=[glucose_(tf)]/([sucrose_(t0)]×(180/342))

and

% G _(leucrose)=[leucrose_(tf)]/[sucrose_(t0)]

where [glucose_(tf)] and [leucrose_(tf)] correspond to the finalconcentrations of glucose and leucrose at the end of the reaction and[sucrose_(t0)] corresponds to that of the initial substrate (g/l).

The percentage of glucosyl residues incorporated into the HMW polymerwas determined by HPSEC analyses using the formula:

% G _(dextran)=surface area_(dextran-tf)/(surfacearea_(sucrose-t0)/(162/342))

in which surface area_(dextran tf) corresponds to the surface area ofthe dextran peak, determined using the HPSEC chromatogram at the end ofthe reaction, and surface area_(sucrose-t0) corresponds to that of thepeak of the initial substrate. For a given concentration, the surfaceobtained by refractometry is identical regardless of the sugar.

The proportion of glucosyl units incorporated into the IMW polymers oroligosaccharides for which the concentration could not be directlyquantified by HPAEC-PAD or HPSEC was determined using the formula:

% G _(IMW)=100−% G _(glucose-tf)−% G _(leucrose-tf)−% G _(dextran-tf)

The elution profiles of the four dextrans obtained by HPSEC are shown inFIG. 9. Different populations can be distinguished: a first peak elutedat 38 minutes, corresponding to the high molar mass polymer (HMW), and asecond peak at 75 minutes corresponding to fructose, glucose, leucrose(5-O-α-D glucosyl fructose) and other oligosaccharides with a degree ofpolymerization (DP) of less than 7, not separated by the system or invery low concentrations. Between these two principal peaks, as indicatedby the base line perturbations, the products of intermediate size (IMWdextrans) were also present. These compounds, with very variable sizes,between 1000 and 10⁷ Da, were highly polydispersed and in very lowconcentrations, which explains their low intensity on the chromatogram.HPAEC-PAD analyses confirmed their presence, however (results notshown).

The relative quantity of glucosyl units derived from sucrose andincorporated into the different products is listed below in Table 2. Thesynthesis yield for HMW dextran represents about 60% of the glucosylunits for each of the preparations. The transfer of glucosyl units towater (glucose) or fructose (leucrose) represents less than 8%, whilethe synthesis of intermediate size dextrans (IMW) accounted for 25% to32% of the transferred glucosyl units. All of the recombinant forms ofDSR-S tended to synthesize more intermediate size dextrans. The HPSECanalyses also showed that the native enzyme appeared to synthesize twodifferent populations of dextran, as opposed to only one for therecombinant enzymes. The molar mass of HMW dextrans was determined bylight diffusion and estimated to be over 10⁷ g/mol for all of thesamples (exclusion limit of the columns used).

TABLE 2 Percentage of glucosyl units incorporated into the variousproducts derived from the synthesis of dextran at 25° C. and 100 g/l ofsucrose, for the four cited DSR-S preparations HMW dextrans IMW HMWGlucose Leucrose dextrans Rel % (g/mol) Native 4.12 5.80 25.60 64.47 1.5 × 10⁸ DSR-S 8.88 × 10⁷ Entire DSR-S 2.32 5.39 29.32 62.96 1.86 ×10⁸ DSR-S 2.43 5.90 31.03 60.64 4.87 × 10⁷ vardel Δ4N Purified 2.33 5.8032.24 59.62 2.47 × 10⁷ DSR-S vardel Δ4N

Structure of Dextrans Formed

The structure of the dextran produced by DSR-S vardel Δ4N (purified orotherwise) was compared with that of dextrans synthesized from entirerecombinant DSR-S and native DSR-S. These structures were determined bynuclear magnetic resonance (¹H NMR) using a Brücker AC 300, at 85° C.and with an acquisition frequency of 300.13 MHz. The acquisition timewas 3 s, with 32 to 64 passes. The dextrans were initially separatedfrom the co-produced fructose by precipitating 3 times with 1 volume ofabsolute ethanol, recovered by centrifuging, washed with distilled waterand freeze dried. The samples were dissolved in D₂O to a concentrationof 6 mg/ml.

The NMR spectra are shown in FIG. 10. Only α-1,6 bonds were detected.Carbon-13 NMR analysis was also carried out on the dextran synthesizedby purified DSR-S vardel Δ4N. The spectrum obtained was identical tothose published for the dextran from L. mesenteroides NRRL B-512F andentire DSR-S [3].

These polymers were also digested with endodextranase from Chaetomiumgracile carried out for 16 h at 37° C. with 3 enzyme units per ml ofsynthesis medium. The digestion products were analyzed by HPAEC-PAD(FIG. 11). The digestion profiles obtained were identical for the fouranalyzed dextrans, confirming that they all had at least 95% α-1,6bonds.

The deletions made in the N and C-terminal positions of the DSR-S toconstruct the DSR-S vardel Δ4N variant thus have no significantinfluence on the initial activity of DSR-S or on the portion of glucosylunits derived from sucrose incorporated into the synthesis of the HMWdextran, the size or the structure of the polysaccharide.

Rheological Behavior of Dextrans Formed

The rheological behavior of the four dextrans was analyzed using acone-plane system (AR 1000, TA Instruments) provided with a 4 cmdiameter cone at an angle of 3.59°, and covering speeds of 0.01 to 100s⁻¹. The measurements were carried out at 25° C. Dynamic experimentswere carried out in the linear domain between 0 and 10 Pa, with adeformation of 8% for the dextran synthesized by native DSR-S from L.mesenteroides NRRL B-512F (control), 3% for that synthesized by theentire recombinant DSR-S, 5% for that synthesized by a non-purifiedextract of DSR-S vardel Δ4N and 0.4% for that synthesized by purifiedDSR-S vardel Δ4N The complex stiffness modulus is defined by therelationship:

G*(ω)=G′(ω)+iG″(ω).

The energy conservation modulus G′(ω) is larger when the sample ispredominantly elastic or highly structured. The loss modulus G″(ω)represents the energy dissipated during deformation. Predominantlyviscous samples have a high G″ (ω).

These rheological analyses produced entirely original results (FIG. 12).As described in the literature, native DSR-S synthesized a dextran withNewtonian behavior [25].

The entire recombinant DSR-S extracts and non-purified DSR-S vardel Δ4Nextracts produced viscous solutions with identical behavior (viscosityabout 10 times higher than that of dextran produced by native enzyme).When observed with the naked eye, they also had a fairly pronouncedstringy behavior. Further, after application of new shear stresses, thebehavior of said polymers changed from a solution type to a gel type,which is a novel property which has been identified for this type ofbiopolymer. The dextran produced by the native enzyme, in contrast, wasnot stringy, and its behavior was entirely reversible after applicationof a second series of stresses (FIG. 12A).

The purified enzyme directly synthesized a polymer having the propertiesof a highly structured gel (FIG. 12B, modulus G′ much higher than G″),retaining its characteristics through a range of temperatures from 10°C. to 70° C. (results not shown). This behavior is completely differentfrom that of the native enzyme.

Only the preparation of purified DSR-S vardel Δ4N contained only oneactive dextransucrase in the extract. Native DSR-S is known to be proneto problems of proteolytic degradation [26] and the purificationtechniques developed could not resolve that problem [27, 28, 29]. Entirerecombinant DSR-S used in the test contained at least two activeenzymatic forms, like the DSR-S vardel Δ4N preparation prior topurification. However, the degraded forms of native DSR-S, entirerecombinant DSR-S and DSR-S vardel Δ4N are entirely different. It iscurrently assumed that cooperation between these different activeenzymatic forms present in the medium could be the origin ofmodifications to the dextran chains, causing these differences inbehavior.

Example 6 Synthesis of Isomaltose from Sucrose

The capacity of mutant DSR-S vardel Δ4N SEV663YDA to synthesize onlyisomaltose (IMO with DP 2) from sucrose to the detriment of high molarmass dextrans was studied.

The mutant was purified by affinity chromatography using the proceduredescribed for DSR-S vardel Δ4N given in Example 3.

The activity was assayed at 30° C.

With a specific activity of only 9 U/mg, the SEV663YDA mutations inducedsevere effects on the activity of DSR-S (loss of 98% of the initialsucrose consumption rate). That specific activity, however, isequivalent to that of recombinant amylosucrase from N. polysaccharea[32], which has been widely studied for its application potential.

The characterizations which were carried out demonstrate the feasibilityof producing isomaltose by this mutant DSR-S, while the wild enzymeproduces only high molar mass dextrans. Syntheses were carried out at25° C. in a buffer containing a concentration of 50 mM of sodium acetateat a pH of 5.2 and 0.05 g/l of CaCl₂, 1 U/ml of purified enzyme andusing 100 g/l of sucrose as the only substrate, or by acceptor reactionstarting with 100 g/l of sucrose and 50 g/l of glucose. Exhaustion ofsucrose was monitored by HPAEC-PAD analyses (see Example 4 for analysisconditions) and the reactions were interrupted after completeconsumption.

Isomaltose production thus reached a yield of 47% using sucrose as theonly substrate (Table 3 and FIG. 13), a yield which was equivalent tothat obtained by the acceptor reaction. Adding an exogenous acceptor wasthus not necessary. Traces of isomaltotriose, maltose or nigerose (notseparated by the system) were also identified (FIG. 13) as well as thepresence of other oligosaccharides with a DP of less than 7 and ofunknown structure.

TABLE 3 Synthesis of isomaltose by mutant DSR-S vardel Δ4N SEV663YDAfrom 100 g/l of sucrose alone, or by acceptor reaction with 50 g/l ofglucose. Concentration of different products present at the end of thereaction. 100 g/l sucrose + 100 g/l sucrose 50 g/l glucose Glucose 16.7333.14 Fructose 45.95 42.31 isomaltose 23.99 47.17 Other oligosaccharides13.33 27.38 % of glucose residues 47.98% 47.17%² transferred toisomaltose ²calculated from glucosyl residues derived from exogenousglucose and sucrose added to medium.

Thus in this Example, the production of isomaltose attained a yield of47%. Currently, this is the first method involving a single enzyme forsynthesizing isomaltose from sucrose; all prior studies being linked tothe degradation of starch by a cocktail of α-amylases and glycosidases[11], or to the joint action of dextransucrase and dextranase [30].Further, sucrose is a cheap and widely available substrate and thefructose released during the syntheses constitute a co-product the valueof which can be exploited separately.

Example 7 Synthesis of Dextran by DSR-S Vardel Δ3

Different enzymatic forms of DSR-S vardel Δ3 were produced duringculture of E. coli TOP10. However, the entire form was vastly in themajority and the zymograms produced (see Example 3) showed that only theentire form was active.

The optimum activity temperature for this variant was 20° C. Thus,activity assays were carried out at this temperature. Production ofDSR-S vardel Δ3 in accordance with Example 2 reached about 320 U/1 ofculture.

Dextran syntheses were carried out at 20° C. in a buffer containing 50mM of sodium acetate, pH of 5.2, and 0.05 g/l of CaCl₂, 100 g/l ofsucrose and 1 U/ml of non-purified DSR-S vardel Δ3 extract. The DSR-Svardel Δ3 extract could be purified by affinity chromatography on nickelresin using the protocol described for DSR-S vardel Δ4N in Example 3.However, since the sonication supernatant contained only a singleenzymatic form of dextransucrase and E. coli did not produce anotherenzyme which could consume the sucrose, purification of the variant didnot constitute a prerequisite for rigorous characterization of itsproperties. By way of comparison, dextran syntheses were carried outunder the same conditions as with (non-purified) DSR-S vardel Δ4N. Thedisappearance of the sucrose was monitored by HPAEC-PAD analyses and thereactions were stopped (5 minutes, 95° C.) after total exhaustion.

The synthesized products were analyzed and quantified by HPAEC-PAD andHPSEC using the conditions described in Example 4. For the HPSECanalyses, the size of the dextrans was estimated using commerciallyavailable dextrans with sizes of 2×10⁶, 503×10³, 70,000, 10,000 Da,maltoheptaose and glucose (Sigma).

As can be seen in FIG. 13, at 20° C. the DSR-S vardel Δ3 variantsynthesized two populations of polymers; major population of HMW dextranwith a size of 2×10⁶ Da, representing about 39% of the glucosyl residuesderived from sucrose (Table 4) and a second population of 1,300 to52,000 Da, centered at the highest peak at around 10,000 Da (about 25%glucosyl residues). This is the first time that a second population ofdextran which is clearly visibly on the HPSEC chromatogram has beenobserved for a DSR-S variant.

Effect of Temperature on the Profile of the Products

Dextran syntheses were also carried out at a temperature of 10° C.,still with a buffer containing 50 mM of sodium acetate, pH 5.2, 0.05 g/lof CaCl₂ and 1 U/ml of enzyme (activity assayed at 20° C.). Sucroseexhaustion was monitored by HPAEC-PAD analyses and the reactions werestopped (5 min, 95° C.) after total consumption thereof.

As can be seen in FIG. 14, at 10° C. the DSR-S vardel Δ3 variantsynthesized a population of dextran which was very different from thatproduced at 20° C. The major polymer (about 44%) formed at thattemperature had a molar mass in the range 7,000 and 1.7×10⁵ Da centeredat the peak at around 40,000 Da.

TABLE 4 Percentage of glucosyl units incorporated into differentproducts synthesized by DSR-S vardel Δ4N nd DSR-S vardel Δ3 at 10° C.and 20° C. starting from 100 g/l of sucrose DSR-S vardel Δ4N DSR-Svardel Δ3 20° C. 10° C. 20° C. 10° C. HMW dextran > 55.2 37.1 39.2 8.8 2× 10⁶ Da Dextran nd¹ nd nd 43.9 40,000 Da Dextran 10,000 Da 18.2 14.724.8 nd Oligosaccharides 16.2 39.1 27.3 36.7 with DP ≦ 8² Leucrose 9.27.6 5.3 9.3 Glucose 1.2 1.5 3.4 1.3 ¹nd: not detected ²degree ofpolymerization calculated from retention time estimated at lower limitof 10000 Da dextran peak.

Effect of Sucrose Concentration

Four increasing concentrations of sucrose were tested (100, 150, 200 and250 g/l) for the dextran syntheses carried out at 20° C. and 10° C. withDSR-S vardel Δ3 (1 U/ml). The total consumption of sucrose was monitoredby HPAEC-PAD analyses and the syntheses were stopped after its totalconsumption (less than 48 h).

For the two temperatures, the initial increase in the concentration ofsubstrate encouraged the synthesis of low molar mass dextrans. At 20°C., the synthesis of 10,000 Da dextran thus changed from a yield of 25%to 48% on changing from 100 to 250 g/l of initial sucrose. At 10° C. andfrom 250 g/l, HMW dextran synthesis was completely abolished, and thatof dextran with the main population with a molar mass centered around40,000 Da advantageously reached a yield of 69%.

For all of the dextrans synthesized by DSR-S vardel Δ3, at 10° C. and20° C., and from 100 to 250 g/l of sucrose, the endodextranase digestionprofiles (see Example 5) carried out confirmed that the bindingspecificity of DSR-S was unchanged (same oligosaccharide profilesdetected by HPAEC-PAD as with DSR-S vardel Δ4N, i.e., at least 95% α-1,6bonds).

Example 8 Synthesis of Dextran by DSR-S Vardel Core and DSR-S Core ΔA

The DSR-S vardel Core and DSR-S Core ΔA variants were also slightlydegraded during expression by E. coli TOP under the conditions describedin Example 2. However, as was the case for the DSR-S vardel Δ3 variant,only the entire form, which was in the vast majority, was activeaccording to the zymogram (results not shown).

The optimum activity temperature for these variants was also 20° C.Production thus reached 38 and 180 U/L of culture for DSR-S vardel Coreand DSR-S Core ΔA respectively.

Dextran syntheses were carried out at 20° C. and 10° C. using 100 to 250g/l of sucrose in a buffer containing 50 mM of sodium acetate, pH 5.2,0.05 g/l of CaCl₂ and 1 U/ml of enzymatic extract (non-purified).Sucrose consumption was monitored by HPAEC-PAD analyses and thesyntheses were stopped (5 min, 95° C.) after complete exhaustion (lessthan 48 h). The products formed were analyzed by HPAEC-PAD and HPSEC andtheir concentration was quantified as described in Example 5.

FIG. 15 shows the profile of the products synthesized at 20° C. by thetwo variants (HPSEC chromatogram). It can clearly be seen that withthese variants, and in contrast to DSR-S vardel Δ4N and DSR-S vardel Δ3,the major population of dextran formed had a molar mass of close to10,000 Da with the base of the peak between 1,300 and 52,000 (at halfheight between 5,000 and 22,000). With the DSR-S Core ΔA variant, thesynthesis of HMW dextran was completely abolished (Table 5). A reductionin temperature to 10° C. could increase the yields of dextran with˜10,000 Da without a significant size difference, as was the case withDSR-S vardel Δ3 (Table 5). Dextran synthesis with the DSR-S Core ΔAvariant thus reached a yield of 75%. An equivalent yield was obtainedwith the DSR-S vardel Core variant when the initial concentration ofsucrose was 250 g/l (results not shown).

TABLE 5 Percentage of glucosyl units incorporated into differentproducts synthesized by DSR-S vardel Core and DSR-S Core ΔA at 10° C.and 20° C. starting from 100 g/l of sucrose DSR-S DSR-S DSR-S vardel Δ4Nvardel Core Core ΔA 20° 10° 20° 10° 20° 10° C. C. C. C. C. C. HMWdextran > 55.2 37.1 9.9 2.4 nd Nd 2 × 10⁶ Da Dextran 10,000 18.2 14.757.5 62.5 64.4 74.5 Da Oligosaccharides 16.2 39.1 19.6 14.8 19.8 10.0with DP ≦ 8² Leucrose 9.2 7.6 6.5 10.2 12.7 12.8 Glucose 1.2 1.5 6.510.1 3.1 2.7 ¹nd: not detected ²degree of polymerization calculated fromretention time estimated at lower limit of 10000 Da dextran peak.

HPAEC-PAD analysis of the dextran synthesized from 100 g/l of sucrose at20° C. by the different variants showed the very high polydispersibilityof the product (FIG. 16), containing isomalto-oligosaccharides with a DPof 2 to a DP of about 60 for DSR-S Core ΔA in particular.

For all of the dextrans synthesized by DSR-S vardel Core and DSR-S CoreΔA at 10° C. and 20° C., and using 100 to 250 g/l of sucrose, theendodextranase digestion profiles (see Example 5) carried out confirmedthat the binding specificity of DSR-S was unchanged (even theoligosaccharide profiles detected by HPAEC-PAD compared with DSR-Svardel Δ4N, thus at least 95% α-1,6 bonds).

Example 9 Acceptor Reaction with Glucose

Acceptor reactions were carried out at 20° C. with a sucrose/glucoseratio of 2 (100 g/l of sucrose, 50 g/l of glucose), 1 U/ml of extract ofDSR-S vardel Δ4N, DSR-S vardel Δ3, DSR-S vardel Core and DSR-S Core ΔAin a buffer containing 50 mM of sodium acetate at a pH of 5.2 and 0.05g/l of CaCl₂. The total consumption of sucrose was monitored byHPAEC-PAD and the reactions were stopped after it had been completelyexhausted. MI of the variants synthesized isomalto-oligosaccharides(IMO) with a DP of 2 to about 30, to the detriment of the synthesis ofpolymer with a higher DP.

However, the yields obtained were higher for the variants truncated of Aunits. Hence, IMO production reached 52% in the case of DSR-S vardel Δ3and 58% for DSR-S vardel Core and DSR-S Core AA, as opposed to 47% inthe case of DSR-S vardel Δ4N. The oligosaccharide distribution was alsomodified (FIG. 17).

For DSR-S vardel Δ3, the proportion of IMO with a DP of 2 to DP of 15was less than that of products synthesized by DSR-S vardel Δ4N. Thesituation was reversed for IMOs with a DP of more than 15.

Similarly, the DSR-S vardel Core and DSR-S Core ΔA mutants were shown toperform better for the synthesis of IMO with a high DP than DSR-S vardelΔ4N or native DSR-S (DP essentially 2 to 15): the production of IMO witha DP of 12 to a DP of 27 was two to five times higher with these twovariants (according to the ratio of the surface areas obtained byHPAEC-PAD).

REFERENCES

-   [1] Monsan, P., Bozonnet, S., Albenne, C., Joucla, G., Willemot, R.    M., & Remaud-Simeon, M. 2001. Homopolysaccharides from lactic acid    bacteria. International Dairy Journal 11, 675-685.-   [2] Coutinho, P. M., & Henrissat, B. 1999, Carbohydrate-Active    Enzymes server.-   [3] Monchois, V., Remaud-Simeon, M., Russell, R. R., Monsan, P., &    Willemot, R. M. 1997. Characterization of Leuconostoc mesenteroides    NRRL B-512F dextransucrase (DSR-S) and identification of amino-acid    residues playing a key role in enzyme activity. Appl. Microbiol.    Biotechnol. 48, 465.-   [4] Koepsell, H. J., Tsuchiya, H. M., Hellman, N. N., Kazenko, A.,    15 Hoffman, C. A., Sharpe, E. S., & Jackson, R. W. 1953. Enzymatic    synthesis of dextran; acceptor specificity and chain initiation. J    Biol Chem 200, 793-801.-   [5] Groenwall, A. J., & Ingelman, G. A. 1948. Manufacture of    infusion and injection fluids. U.S. Pat. No. 2,437,518.-   [6] Robyt, J. F. 1985. Dextran, p. 753-767. In J. I. Kroschwitz    (ed.), Encyclopedia of polymer Science, vol. 4. Wiley-VCH, New-York.-   [7] Ahsan, N. 1998. Intravenous infusion of total dose iron is    superior to oral iron in treatment of anemia in peritoneal dialysis    patients: a single center comparative study. J Am Soc Nephrol 9,    664-8.-   [8] De Belder, A. N. 1996 Medical applications of dextran and its    derivatives p 275-296. In S. Domitriu (ed.), Polysaccharides in    medicinal applications. Marcel Dekker, Inc., New York.-   [9] Jagodzinski, P. P., Lewandowska, M., Januchowski, R.,    Franciszkiewicz, K., & Trzeciak, W. H.2002. The effect of high    molecular weight dextran sulfate on the production of interleukin-8    in monocyte cell culture. Biomed Pharmacother 56, 254-7.-   [10] Hersline, R. 2004. Antiviral composition. U.S. Pat. No.    6,821,958.-   [11] Nakakuki, T. 2002. Present status and future of functional    oligosaccharide development in Japan. Pure App Chem 74, 1245-1251.-   [12] Goulas, A. K., Fisher, D. A., Grimble, G. K. Grandison, A. S.,    & Rastall, R. A. 2004b. Synthesis of isomaltooligosaccharides and    oligodextrans by the combined use of dextransucrase and dextranase.    Enzyme and Microbial Technology 35, 327-338.-   [13] Rousseau, V., Lepargneur, J., Rogues, C., Remaud-Simeon, M., &    Paul, F. 2005. Prebiotic effect of oligosaccharides on selected    vaginal lactobacilli and pathogenic microorganisms. Anaerobe, 11(3),    145-153,-   [14] Goulas, A. K., Cooper, J. M., Grandison, A. S., &    Rastall, R. A. 2004a. Synthesis of isomaltooligosaccharides and    oligodextrans in a recycle membrane bioreactor by the combined use    of dextransucrase and dextranase. Biotechnol Bioeng 88, 778-87.-   [15] Scientific Committee On Food. 2000. Opinion on the scientific    committee on food on a dextran preparation produced using    Leuconostoc mesenteroides, Saccharomyces cerevisiae and    Lactobacillus ssp as a novel food ingredient in bakery products.    European Commission, Health & Consumer Protection    Directorate-General, Brussels.-   [16] Monchois, V., Reverte, A., Remaud-Simeon, M., Monsan, P., &    Willemot, R. M. 1998. Effect of Leuconostoc mesenteroides NRRL    B-512F dextransucrase carboxy-terminal deletions on dextran and    oligosaccharide synthesis. Appl. Environ. Microbiol. 64, 1644-49.-   [17] R. Kaufman, Methods in Enzymology 185, 537-566 (1990)-   [18] Tannock, W. G. Probiotics and Prebiotics. Where are we going?    Caister Academic Press, Wymondham, UK 2002-   [19] Khalikova, E., Susi, P. & Korpela, T., 2005. Microbial    dextran-hydrolyzing enzymes: fundamentals and applications.    Microbial. Mol. Biol. 69, 306-25-   [20] Merrifield, R. B., 1963 J. Am. Chem. Soc. 85,2149.-   [21] Monsan, P., Paul, F., 1995 Enzymatic synthesis of    oligosaccharides FEMS Microbiol. Rev, 16, 187-192.-   [22] Sumner, J., & Howell, S. 1935. A method for determination of    invertase activity. Journal of Biological Chemistry 108, 51.-   [23] Gibson, G. R., Roberfroid, M. B., 1995 Dietary modulation of    the human colonic microbiota: introducing the concept of    prebiotics J. Nutr., 125, 1401-12.-   [24] Paul, F., Auriol, D., Oriol, E., & Monsan, P. 1984. Production    and purification of dextransucrase from Leuconostoc mesenteroides    NRRL B-512F. Ann. N.Y. Acad. Sci. 434, 267-270.-   [25] Carrasco, F., Chornet, E., Overend, R. P., & Costa, J. 1989 A    generalized correlation for the viscosity of dextrans in aqueous    solutions as a function of temperature, concentration, and molecular    weight at low shear rate. J Appl Polymer Sci 37, 2087-98.-   [26] Arguello-Morales, M., Sanchez-Gonzalez. M., Canedo, M.,    Quirasco. M., Farres, A., & Lopez-Munguia, A. 2005. Proteolytic    modification of Leuconostoc mesenteroides B-512F dextransucrase.    Antonie Van Leeuwenhoek 87, 131-41.-   [27] Miller, A. W., Eklund, S. H., & Robyt, J. F. 1986. Milligram to    gram scale purification and characterization of dextransucrase from    Leuconostoc mesenteroides NRRL B-512F. Carbohydr. Res. 147, 119.-   [28] Kobayashi, M., & Matsumada, K. 1986. Electrophoretic analysis    of the multiple forms of dextransucrase from Leuconostoc    mesenteroides. J. Biochem. (Tokyo) 100, 615-   [29] Kobayashi, M., Mihara, K., & Matsuda, K. 1986. Dextransucrase    from Leuconostoc mesenteroides NRRL B-512F: characterization of the    enzyme bound to Sephadex gel. Agric Biol Chem 50, 551-556.-   [30] Paul, F., Monsan, P., Remaud, M., Pelenc, V. Process for    preparing enzymatically a sugar mixture having a high content of    isomaltose from sucrose, U.S. Pat. No. 4,861,381-   [31] Blood Products Committee 83rd Meeting—Jul. 21, 2005-   [32] Potocki-de-Montalk, G., Remaud-Simeon, M., Willemot, R. M.,    Planchot, V., and Monsan, P. 1999. Sequence analysis of the gene    encoding amylosucrase from Neisseria polysaccharea and    characterization of the recombinant enzyme. J. Bacteriol. 181,    375-381.-   [33] Batik, S. 1995. site-directed mutagenesis by double polymerase    chain reaction. Mol Biotechno/3, 1-7.

1. An isolated nucleotide sequence consisting essentially of anucleotide sequence of SEQ ID NO: 4, a full length complementarysequence of SEQ ID NO: 4 or a sequence which hybridizes with the fulllength SEQ ID NO: 4 under stringent hybridization conditions, whereinsaid stringent conditions are 2×SSC, 10×Denhardts solution, 0.1% SDS, 5mM EDTA, 50 mM Na₂HPO₄, 250 μg/ml herring sperm DNA and 50 μg/ml oft-RNA at 60° C. provided that said nucleotide sequence encodes a proteinthat conserves dextransucrase enzymatic activity.
 2. The nucleotidesequence according to claim 1, comprising nucleotide residues 373 to3018 of SEQ ID NO:
 4. 3. A nucleotide sequence according to claim 1, inwhich the nucleotide sequence hybridizes under stringent conditions witha full length nucleotide sequence comprising nucleotide residues 373 to3018 of SEQ. ID NO: 4, wherein said stringent conditions are 2×SSC,10×Denhardts solution, 0.1% SDS, 5 mM EDTA, 50 mM Na₂HPO₄, 250 μg/mlherring sperm DNA and 50 of t-RNA at 60° C. provided that saidnucleotide sequence encodes a protein that conserves the dextransucraseenzymatic activity.
 4. A vector containing a nucleotide sequenceaccording to claim
 1. 5. An isolated host cell transformed by a vectoraccording to claim
 4. 6. A method of preparing a polypeptide havingdextransucrase activity encoded by the polynucleotide sequence of SEQ IDNO: 4, said method comprising culturing host cells transformed by avector comprising said polynucleotide.
 7. The method according to claim6, characterized in that it further comprises a step for purifying theisolated dextransucrase.
 8. A method for producing dextrans orisomalto-oligosaccharides with a controlled molar mass, comprisingreacting with a polypeptide comprising the amino acid SEQ ID NO: 9having dextransucrase activity in the presence of sucrose and optionallywith at least one acceptor.
 9. The method according to claim 8, in whichthe reaction takes place in the presence of at least one acceptorselected from glucose, maltose, isomaltose, fructose,isomalto-oligosaccharides and mixtures thereof, preferably maltose,isomaltose or glucose.
 10. The method according to claim 9,characterized in that the reaction takes place at temperatures in therange 4° C. to 80° C., preferably 4° C. to 40° C.
 11. The methodaccording to claim 9, characterized in that the sucrose concentration isin the range 10 to 600 g/l, preferably 75 to 400 g/l, more preferably 90to 280 g/l.
 12. The method according to claim 11, wherein saidconcentration of sucrose is of the order of 100 g/l.
 13. A dextran whichcan be obtained by the method according to claim 8, with non-Newtonianbehavior.
 14. An isomalto-oligosaccharide which can be obtained by themethod according to claim
 8. 15. An isolated polynucleotide sequenceencoding a protein comprising SEQ ID NO: 9.